IAIM
PTGX icon

Industrial Alliance Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Industrial Alliance Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-56,695
Closed -$1.34M – 417
2022
Q1 		$1.34M Sell
56,695
-18,540
-25% -$522K 0.03% 263
2021
Q4 		$2.57M Buy
+75,235
New +$2.38M 0.06% 218

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Industrial Alliance Investment Management's PTGX Position: Q2 2022 in Review

Industrial Alliance Investment Management sold out of Protagonist Therapeutics (PTGX) in Q2 2022, closing a stake of 56,695 shares — an estimated $1.34M sold.

Industrial Alliance Investment Management first reported a position in PTGX in Q4 2021 and held it in 2 quarters. The position peaked at $2.57M in Q4 2021. 130 funds tracked by Wall St. Rank hold PTGX as of Q2 2022.

  • Industrial Alliance Investment Management reported no remaining Protagonist Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Industrial Alliance Investment Management sold 56,695 Protagonist Therapeutics shares in Q2 2022, an estimated $1.34M.
  • Industrial Alliance Investment Management first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 2 quarters.
  • Industrial Alliance Investment Management's Protagonist Therapeutics position peaked at $2.57M in Q4 2021.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2022.

Based on Industrial Alliance Investment Management's 13F filing for Q2 2022, filed 10 Aug 2022.